C22orf36 Blocking Peptide
- Known as:
- C22orf36 Blocking Peptide
- Catalog number:
- 33r-9965
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Fitzgerald industries international
- Gene target:
- C22orf36 Blocking Peptide
Related genes to: C22orf36 Blocking Peptide
- Gene:
- LRRC75B NIH gene
- Name:
- leucine rich repeat containing 75B
- Previous symbol:
- C22orf36, FAM211B
- Synonyms:
- MGC131773
- Chromosome:
- 22q11.23
- Locus Type:
- gene with protein product
- Date approved:
- 2006-10-16
- Date modifiied:
- 2014-11-19
Related products to: C22orf36 Blocking Peptide
Related articles to: C22orf36 Blocking Peptide
- Integrating protein-coding gene (PCG) with long noncoding RNA (lncRNA) expression profiles, our aim is to identify a multidimensional transcriptome model that can predict individual prognosis of patients with breast cancer (BRCA). After diverse bioinformatics and statistical analyses, we obtained gene expression profiles of 1,016 BRCA samples from Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) database, and constructed a prognostic signature, which is composed of four PCGs (TFCP2, LRRC75B, PROSER2, and STOML1) and one lncRNA (AL355592.1). In the training set, the multidimensional transcriptome signature could part patients with BRCA into two groups with different survival, defined as high- and low-risk group by Kaplan-Meier (KM) analysis (p < 0.001). In the other five validation datasets, the PCG-lncRNA signature showed a similar predictive performance in BRCA by KM (p < 0.05). The prognostic independence for the PCG-lncRNA model was verified by the multivariable Cox regression analysis. Because Chi-squared test showed the signature was associated with lymph node metastasis status, stratification analysis found that it could further subdivide lymph node metastasis status more precisely in BRCA. The function analysis suggested that the genes from the signature were associated with immunity-related pathways. In summary, we constructed a PCG-lncRNA signature, which could accurately predict survival in patients with BRCA. - Source: PubMed
Publication date: 2019/04/04
Sui YujieJu ChunyanShao Bin - Many transcription factors and signaling molecules involved in the guidance of myogenic differentiation have been investigated in previous studies. However, the precise molecular mechanisms of myogenic differentiation remain largely unknown. In the present study, by performing a meta-analysis of C2C12 myogenic differentiation microarray data, we found that leucine-rich repeat-containing 75B (Lrrc75b), also known as AI646023, a molecule of unknown biological function, was downregulated during C2C12 myogenic differentiation. The knockdown of Lrrc75b using specific siRNA in C2C12 myoblasts markedly enhanced the expression of muscle-specific myogenin and increased myoblast fusion and the myotube diameter. By contrast, the adenovirus-mediated overexpression of Lrrc75b in C2C12 cells markedly inhibited myoblast differentiation accompanied by a decrease in myogenin expression. In addition, the phosphorylation of extracellular signal-regulated kinase 1/2 (Erk1/2) was suppressed in the cells in which Lrrc75b was silenced. Taken together, our results demonstrate that Lrrc75b is a novel suppressor of C2C12 myogenic differentiation by modulating myogenin and Erk1/2 signaling. - Source: PubMed
Publication date: 2016/09/15
Zhong YuechunZou LiyiWang ZongguiPan YaqiongDai ZhongLiu XinguangCui LiaoZuo Changqing